BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 338
- Registration Number
- NCT04909801
- Locations
- 🇮🇹
Local Institution - 0083, Catania, Italy
🇮🇹Local Institution - 0077, Pavia, Italy
🇺🇸Local Institution - 0036, Fullerton, California, United States
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 650
- Registration Number
- NCT04908202
- Locations
- 🇨🇳
Local Institution - 0122, Tainan, Taiwan
🇨🇳Local Institution - 0120, Taipei City, Taiwan
🇨🇳Local Institution - 0124, Taoyuan, Taiwan
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 729
- Registration Number
- NCT04908189
- Locations
- 🇦🇷
Local Institution - 0200, Buenos Aires, Argentina
🇦🇺Local Institution - 0018, Paramatta, New South Wales, Australia
🇦🇺Local Institution - 0002, Camberwell, Victoria, Australia
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 905
- Registration Number
- NCT04895709
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS Universita Cattolica del Sacro Cuore, Roma, Italy
🇪🇸Institut Catalan d Oncologia (ICO) - Badalona, Badalona, Barcelona [Barcelona], Spain
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 268
- Registration Number
- NCT04895696
- Locations
- 🇺🇸
Local Institution - 0137, South Miami, Florida, United States
🇺🇸Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States
🇺🇸Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States
A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04882150
- Locations
- 🇺🇸
Local Institution - 0002, Salt Lake City, Utah, United States
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04877288
- Locations
- 🇺🇸
Local Institution - 0038, Seattle, Washington, United States
🇺🇸Local Institution - 0045, Miami, Florida, United States
🇺🇸Local Institution - 0022, Hollywood, Florida, United States
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT04877990
- Locations
- 🇺🇸
Local Institution - 0036, Shreveport, Louisiana, United States
🇯🇵Local Institution - 0026, Bunkyo-ku, Tokyo, Japan
🇺🇸Local Institution - 0002, Wyoming, Michigan, United States
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT04857034
- Locations
- 🇲🇽
Local Institution - 0071, Mexico City, Mexico
🇨🇳Local Institution - 0022, Taipei, Taiwan
🇺🇸Local Institution - 0059, Saint Louis, Missouri, United States
A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan
- Conditions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9282
- Registration Number
- NCT04828772
- Locations
- 🇯🇵
Medical Data Vision, Tokyo, Japan
🇯🇵Local Institution, Minato-ku, Tokyo, Japan